Electrophysiological profile of propiverine – relationship to cardiac risk

Drugs that prolong the QT interval by blocking human ether-a-go-go (HERG) channels may enhance the risk of ventricular arrhythmia. The spasmolytic drug propiverine is widely used for the therapy of overactive bladder (OAB). Here, we have investigated the effects of propiverine on cardiac ion channels and action potentials as well as on contractile properties of cardiac tissue, in order to estimate its cardiac safety profile, because other drugs used in this indication had to be withdrawn due to safety reasons. Whole-cell patch clamp technique was used to record the following cardiac ion currents: rapidly and slowly activating delayed rectifier K+ current (IKr, IKs), ultra rapidly activating delayed rectifier K+ current (IKur), inwardly rectifying K+ current IK1, transient outward K+ current (Ito), and L-type Ca2+ current (ICa,L). Action potentials in cardiac tissue biopsies were recorded with conventional microelectrodes. The torsade de pointes screening assay (TDPScreenTM) was used for drug scoring. Propiverine blocked in a concentration-dependent manner HERG channels expressed in HEK293 cells, as well as native IKr current in ventricular myocytes of guinea pig (IC50 values: 10 μM and 1.8 μM respectively). At high concentrations (100 μM), propiverine suppressed IKs. IK1 and the transient outward current Ito and IKur were not affected. In guinea-pig ventricular and human atrial myocytes, propiverine also blocked ICa,L (IC50 values: 34.7 μM and 41.7 μM, respectively) and reduced force of contraction. Despite block of IKr, action potential duration was not prolonged in guinea-pig and human ventricular tissue, but decreased progressively until excitation failed altogether. Similar effects were observed in dog Purkinje fibers. Propiverine obtained a low score in the TDPScreenTM. In conclusion, in vitro and in vivo studies of propiverine do not provide evidence for an enhanced cardiovascular safety risk. We propose that lack of torsadogenic risk of propiverine is related to enhancement of repolarization reserve by block of ICa,L.

[1]  U. Ravens,et al.  Risperidone-induced action potential prolongation is attenuated by increased repolarization reserve due to concomitant block of ICa,L , 2005, Naunyn-Schmiedeberg's Archives of Pharmacology.

[2]  Gary A Gintant,et al.  In Vitro Preclinical Cardiac Assessment of Tolterodine and Terodiline: Multiple Factors Predict the Clinical Experience , 2006, Journal of cardiovascular pharmacology.

[3]  G. Duker,et al.  Instability and Triangulation of the Action Potential Predict Serious Proarrhythmia, but Action Potential Duration Prolongation Is Antiarrhythmic , 2001, Circulation.

[4]  M. Siepmann,et al.  Pharmacokinetics and safety of propiverine in patients with fatty liver disease , 1998, European Journal of Clinical Pharmacology.

[5]  L A Moyé,et al.  The cardiac arrhythmia suppression trial. Casting suppression in a different light. , 1995, Circulation.

[6]  C. Valdivia,et al.  Drug‐induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine , 2006, British journal of pharmacology.

[7]  T. Ogura,et al.  Analysis of the electrophysiologic effects of short-term oxybutynin on guinea pig and rabbit ventricular cells. , 2000, Journal of cardiovascular pharmacology.

[8]  Serge Richard,et al.  Prediction of the risk of Torsade de Pointes using the model of isolated canine Purkinje fibres , 2005, British journal of pharmacology.

[9]  D. Attwell,et al.  The steady state TTX-sensitive (“window”) sodium current in cardiac Purkinje fibres , 1979, Pflügers Archiv.

[10]  K. Matschke,et al.  An aqueous extract of the marine sponge Ectyoplasia ferox stimulates L-type Ca2+-current by direct interaction with the Cav1.2 subunit , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[11]  T. Ogura,et al.  Inhibition of the rapid component of the delayed‐rectifier K+ current by therapeutic concentrations of the antispasmodic agent terodiline , 1998, British journal of pharmacology.

[12]  B. Sakmann,et al.  Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches , 1981, Pflügers Archiv.

[13]  Hani N Sabbah,et al.  Ranolazine Improves Abnormal Repolarization and Contraction in Left Ventricular Myocytes of Dogs with Heart Failure by Inhibiting Late Sodium Current , 2006, Journal of cardiovascular electrophysiology.

[14]  A. Camm,et al.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.

[15]  J. Stolzenburg,et al.  Efficacy and Cardiac Safety of Propiverine in Elderly Patients – A Double–Blind, Placebo–Controlled Clinical Study , 2000, European Urology.

[16]  J. Cowan,et al.  Torsades de pointes ventricular tachycardia and terodiline , 1991, The Lancet.

[17]  M. Wuest,et al.  Pharmacodynamics of propiverine and three of its main metabolites on detrusor contraction , 2005, British journal of pharmacology.

[18]  M. Michel,et al.  Treatment of the overactive bladder syndrome with muscarinic receptor antagonists - a matter of metabolites? , 2006, Naunyn-Schmiedeberg's Archives of Pharmacology.

[19]  G. Bett,et al.  Ancillary subunits and stimulation frequency determine the potency of chromanol 293B block of the KCNQ1 potassium channel , 2006, The Journal of physiology.

[20]  J. Tamargo.  Drug-induced torsade de pointes: from molecular biology to bedside. , 2000, Japanese journal of pharmacology.

[21]  U Ravens,et al.  Differences between outward currents of human atrial and subepicardial ventricular myocytes. , 1996, The Journal of physiology.

[22]  M. Sanguinetti,et al.  Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents , 1990, The Journal of general physiology.

[23]  R Lazzara,et al.  Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. , 1996, Circulation.

[24]  Icilio Cavero,et al.  ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: a critical analysis , 2005, Expert opinion on drug safety.

[25]  H L Greene,et al.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.

[26]  L. Hondeghem.  Thorough QT/QTc Not So Thorough: Removes Torsadogenic Predictors from the T‐Wave, Incriminates Safe Drugs, and Misses Profibrillatory Drugs , 2006, Journal of cardiovascular electrophysiology.

[27]  D. Roden.  Taking the “Idio” out of “Idiosyncratic”: Predicting Torsades de Pointes , 1998, Pacing and clinical electrophysiology : PACE.

[28]  C. January,et al.  Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. , 1998, Biophysical journal.

[29]  L. Shuba,et al.  Differences in the effects of urinary incontinence agents S‐oxybutynin and terodiline on cardiac K+ currents and action potentials , 2000, British journal of pharmacology.

[30]  Andrea Brüggemann,et al.  Inhibition of IKs channels by HMR 1556 , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.

[31]  Jiesheng Kang,et al.  Cardiac Ion Channel Effects of Tolterodine , 2004, Journal of Pharmacology and Experimental Therapeutics.

[32]  H. Madersbacher,et al.  Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic) , 2001, World Journal of Urology.

[33]  J. Papp,et al.  Interaction of different potassium channels in cardiac repolarization in dog ventricular preparations: role of repolarization reserve , 2002, British journal of pharmacology.

[34]  C. January,et al.  Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. , 1999, Circulation research.

[35]  R. Hauer,et al.  Genetic and molecular basis of cardiac arrhythmias : Impact on clinical management , 1999 .

[36]  A. A. Mcleod,et al.  Torsades de pointes complicating treatment with terodiline. , 1991, BMJ.

[37]  A. Camm,et al.  Congenital and acquired long QT syndrome. , 2000, European heart journal.

[38]  R. Campbell,et al.  Concentration dependent cardiotoxicity of terodiline in patients treated for urinary incontinence. , 1995, British heart journal.

[39]  R. Dmochowski,et al.  The q-t interval and antimuscarinic drugs , 2005, Current urology reports.

[40]  M. Wuest,et al.  Propiverine and metabolites: differences in binding to muscarinic receptors and in functional models of detrusor contraction , 2006, Naunyn-Schmiedeberg's Archives of Pharmacology.

[41]  Gary A Gintant,et al.  The Utility of hERG and Repolarization Assays in Evaluating Delayed Cardiac Repolarization: Influence of Multi-Channel Block , 2004, Journal of cardiovascular pharmacology.